The FDA has announced plans to accelerate the review of three psychedelic substances that may serve as treatments for mental health conditions.
This decision is reportedly influenced by a shift in political perspectives, particularly with former President Trump's recent support for psychedelics and cannabis.
As the GOP's stance on mind-altering substances evolves, the implications for mental health treatment and regulatory practices could be significant.